Posts by Shiv Pillai, MD, PhD
-
Study Seeks FDA-approved Therapy for IgG4-related Disease
Massachusetts General Hospital is conducting an NIH-funded clinical trial exploring elotuzumab as a treatment for IgG4-related disease.
Biography
Shiv Pillai, MD, PhD, is a principal investigator at the Ragon Institute of MGH, MIT and Harvard, an associate geneticist in the Center for Cancer Research at Massachusetts General Hospital and a professor of medicine at Harvard Medical School.
Rheumatology, Allergy and Immunology
The Division of Rheumatology, Allergy and Immunology at Massachusetts General Hospital provides leading-edge treatment and transformative care to patients with rheumatic disease and autoimmune conditions.